{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:44:19Z","timestamp":1783943059239,"version":"3.55.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The 2020 consensus guidelines for drug monitoring of vancomycin recommended AUC-guided dosing to reduce acute kidney injury (AKI) and improve clinical outcomes in patients with serious methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (MRSA) infections previously managed with trough concentrations of 15\u201320\u00a0mg\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To determine if AUC-guided dosing of vancomycin reduces AKI and improves clinical outcomes including non-invasive infections with\n                      <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                      compared with trough-only dosing broadened to concentrations of 10\u201320\u00a0mg\/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective, single-center, cohort study was conducted over 12\u00a0months comparing Bayesian software-guided AUC-dosing with trough-only dosing. Information collected included patient demographics, co-morbidities, concurrent nephrotoxins, assessment measures of drug exposure, and patient outcomes. Nominal data were analyzed using the chi-square test, and continuous data using the independent\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria, the incidence of AKI was 7.65% and 6.06% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.56), among 183 patients in the AUC-guided and 165 subjects in the trough-only groups, respectively. Individuals in the trough-only group were younger, had fewer co-morbidities and admissions to the ICU. A lower incidence of AKI findings among trough-only subjects was likely a result of the duration of therapy (mean of 4.2\u00a0days), mean trough concentrations &lt;15\u00a0mg\/L, and fewer concurrent nephrotoxins. AUC-guided dosing significantly reduced the total daily dose, 2.29 vs 2.54\u00a0g\/day (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01), but provided no significant reductions in cumulative dose, duration of therapy, length of hospital stays, or overall patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AUC-guided vancomycin dosing did not reduce the incidence of AKI nor impact patient outcomes vs trough-only dosing. Successful clinical outcomes with lower average trough concentrations may have resulted from the treatment of nonbacteremic skin soft tissue infections (SSTI), suggesting an indication for further exploration of vancomycin dosing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08971900251338904","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:09:40Z","timestamp":1746500980000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Implementation of AUC-Guided Vancomycin Dosing: What Role Remains for Trough-Only Monitoring? A Retrospective, Cohort Study"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1504-5522","authenticated-orcid":false,"given":"Robert","family":"Barrons","sequence":"first","affiliation":[{"name":"Wingate University School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8351","authenticated-orcid":false,"given":"Edward","family":"Chiyaka","sequence":"additional","affiliation":[{"name":"Wingate University School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0764-7"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4409-751"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-12"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211012395"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.3337"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.4.433"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.030"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001075"},{"issue":"4","key":"e_1_3_5_12_2","first-page":"c179\u201384","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Kdigo-Khwaja A","year":"2012","unstructured":"Kdigo-Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u201384.","journal-title":"Nephron Clin Pract"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-016-2252-7"},{"issue":"1","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"e0088621","DOI":"10.1128\/AAC.00886-21","article-title":"Acute kidney injury associated with area under the curve versus trough monitoring of vancomycin in obese patients","volume":"66","author":"D'Amico H","year":"2022","unstructured":"D'Amico H, Wallace KL, Burgess D, et al. Acute kidney injury associated with area under the curve versus trough monitoring of vancomycin in obese patients. Antimicrob Agents Chemother. 2022;66(1):e0088621.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01293-17"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa114"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2482"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190018800093"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.05.011"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02042-17"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106234"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106109"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0236-z"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2023-2-1"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1026"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz070"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251338904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251338904","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251338904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:50Z","timestamp":1777509230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251338904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/08971900251338904"],"URL":"https:\/\/doi.org\/10.1177\/08971900251338904","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}